Last Updated: April 29, 2026

CLINICAL TRIALS PROFILE FOR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00528879 ↗ A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed Bristol-Myers Squibb Phase 3 2007-09-01 The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied.
NCT00528879 ↗ A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone Completed AstraZeneca Phase 3 2007-09-01 The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied.
NCT00546741 ↗ Drug Interaction With Metformin Completed Bristol-Myers Squibb Phase 1 2007-11-01 The purpose of the study is to determine the effect of metformin on dapagliflozin exposure and the effect of dapagliflozin on metformin exposure in healthy volunteers. Additionally, the safety and tolerability of dapagliflozin will be assessed in the presence and absence of metformin in healthy volunteers
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Condition Name

Condition Name for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Intervention Trials
Type 2 Diabetes 26
Type 2 Diabetes Mellitus 20
Diabetes Mellitus, Type 2 18
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Intervention Trials
Diabetes Mellitus, Type 2 81
Diabetes Mellitus 75
Prediabetic State 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Trials by Country

Trials by Country for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Location Trials
United States 295
Mexico 52
China 37
Canada 36
Korea, Republic of 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Location Trials
Texas 22
Florida 16
California 16
Tennessee 13
South Carolina 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Clinical Trial Phase Trials
PHASE4 11
PHASE3 6
PHASE2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 58
Recruiting 32
Not yet recruiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Sponsor Name

Sponsor Name for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Sponsor Trials
AstraZeneca 53
Bristol-Myers Squibb 12
LG Chem 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Sponsor Trials
Other 113
Industry 96
OTHER_GOV 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.